Opinion on drug spending reduction due to biosimilars for specialty drugs 2017-2020

Published by
Matej Mikulic,
Aug 13, 2019
This statistic shows the percentage of U.S. health care executives who foresee biosimilars reducing drug spend for specialty drugs in 2017 to 2020. Nearly nine percent of executives stated they think drug spending reduction due to biosimilars will come into effect in 2017, while 25 percent think it will happen in 2020.

Percentage of U.S. health care executives who foresee biosimilars reducing drug spend for specialty drugs in 2017-2020*

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

May 2018

Region

United States

Survey time period

as of December 2015

Number of respondents

228 respondents

Special properties

executives involved in health care industry

Supplementary notes

* Executives at medical practices, hospitals, large healthcare systems, benefit management organizations, health plans, long-term care organizations, group purchasing organizations and consulting firms.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Generics and biosimilars "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Generics and biosimilars

Global overview

4

Top companies

4

U.S. market

6

Patent expiration

6

Savings

7

Biosimilars

7

Further related statistics

17

Further Content: You might find this interesting as well

Statistics

Topics

Pharmaceutical market in the NetherlandsGlobal pharmaceutical industryHealth insurance in the NetherlandsPharmaceutical market in ItalyPharmaceutical industry in Sweden
All features, all contents, at all times: Learn more about our professional solutions.

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.
Menu